Paras Healthcare IPO GMP

Paras Healthcare IPO 2026 is a Mainboard book-built issue of ₹1,450 crore, comprising a fresh issue of ₹500 crore and an Offer for Sale (OFS) of ₹950 crore. The company has fixed the price band at ₹660 to ₹693 per share, with a reported lot size of 21 sha

Today (28 October 2026)
₹13
Est. listing price₹706
Est. listing gain1.88%

Paras Healthcare IPO GMP Today

Day-wise grey market premium. Est. listing = price cap (₹693) + GMP.

⚠GMP is unofficial and highly volatile. The Top Stock Broker does not deal in or facilitate grey-market trading.
GMP DateGMP (₹)Sub2 (₹)Kostak (₹)Est. Listing (₹)Est. Gain
28 October 2026 ₹13 — — ₹706 +1.9%
27 October 2026 ₹13 — — ₹706 +1.9%
26 October 2026 ₹11 — — ₹704 +1.6%
25 October 2026 ₹9 — — ₹702 +1.3%
24 October 2026 ₹12 — — ₹705 +1.7%
23 October 2026 ₹11 — — ₹704 +1.6%
22 October 2026 ₹13 — — ₹706 +1.9%
21 October 2026 ₹25 — — ₹718 +3.6%
20 October 2026 ₹50 — — ₹743 +7.2%
19 October 2026 ₹78 — — ₹771 +11.3%
18 October 2026 ₹96 — — ₹789 +13.9%
17 October 2026 ₹96 — — ₹789 +13.9%
16 October 2026 ₹95 — — ₹788 +13.7%
15 October 2026 ₹85 — — ₹778 +12.3%
14 October 2026 ₹83 — — ₹776 +12%

GMP → Listing Price Calculator

Enter a GMP to estimate listing price, gain and profit per lot. A math estimate only.

Estimated listing price—
Estimated listing gain—
Investment per lot—
Est. profit per lot—

Paras Healthcare IPO Details

IPO Open
Oct 21, 2026
IPO Close
Oct 23, 2026
Price Band
₹660 – ₹693
Lot Size
21 shares
Issue Size
₹1,450 Cr
Face Value
₹1
Allotment Date
Oct 26, 2026
Listing Date
Oct 28, 2026

See the full Paras Healthcare IPO details & review →

What is Paras Healthcare IPO GMP?

Paras Healthcare IPO GMP is the unofficial premium or discount at which its shares are reportedly traded in the grey market before the official stock exchange listing. It can offer an indication of sentiment but does not guarantee the listing price or any investment return.

What is the Current Paras Healthcare IPO GMP?

A reliable current GMP figure has not been independently verified for October 15, 2026. The value should be updated when a credible, dated report becomes available. Investors should not rely on unverified grey-market quotes when making investment decisions.

What is the Expected Listing Price of Paras Healthcare IPO?

The expected listing price is often estimated by adding the GMP to the IPO issue price. With the reported upper price band of ₹693, the indicative calculation would be ₹693 plus the applicable GMP. Since a reliable GMP value has not been confirmed, an expected listing price cannot be calculated responsibly.

Is Paras Healthcare IPO GMP an Official Indicator?

No. GMP is an unofficial grey-market indicator and is not an official stock exchange price. It may fluctuate significantly before listing and does not guarantee the price at which shares will trade on BSE or NSE.

Should Investors Apply Based Only on Paras Healthcare IPO GMP?

No. Investors should evaluate the company's financial performance, valuation, borrowings, expansion plans, business risks and official offer documents. GMP should be treated as an unofficial sentiment indicator rather than the sole basis for an investment decision.

Frequently Asked Questions

The final recorded grey market premium (GMP) of Paras Healthcare IPO was approximately ₹13 per share against the issue price of ₹693, indicating an estimated premium of 1.88% before listing.

Based on the final GMP of ₹13 and the issue price of ₹693, the estimated listing price was ₹706 per share. This was only a grey market estimate and not a guaranteed listing price.

The tracked GMP reached a high of ₹96 per share on 17 October 2026, reflecting strong initial grey market sentiment.

No. Based on the final GMP of ₹13, the estimated listing price was ₹706. However, Paras Healthcare shares actually listed at ₹720 per share on 28 October 2026, giving a listing gain of ₹27 or approximately 3.90% over the issue price of ₹693.

No. GMP is an unofficial indicator of grey market sentiment and is not regulated or guaranteed. The actual listing price may differ depending on market conditions, investor demand, and overall sentiment. Investors should not make investment decisions based on GMP alone.